Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
Ipsen MB, Sørensen EMG, Thomsen EA, Weiss S, Haldrup J, Dalby A, Palmfeldt J, Bross P, Rasmussen M, Fredsøe J, Klingenberg S, Jochumsen MR, Bouchelouche K, Ulhøi BP, Borre M, Mikkelsen JG, Sørensen KD. Ipsen MB, et al. Among authors: sorensen emg, sorensen kd. Oncogene. 2022 Sep;41(37):4271-4281. doi: 10.1038/s41388-022-02427-2. Epub 2022 Aug 6. Oncogene. 2022. PMID: 35933519
Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.
Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhøffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Tørring N, Dyrskjøt L, Andersen CL, Orntoft TF. Thorsen K, et al. Among authors: sorensen kd. Mol Cell Proteomics. 2008 Jul;7(7):1214-24. doi: 10.1074/mcp.M700590-MCP200. Epub 2008 Mar 18. Mol Cell Proteomics. 2008. PMID: 18353764 Free article.
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L. Sørensen KD, et al. Clin Cancer Res. 2009 Feb 15;15(4):1400-10. doi: 10.1158/1078-0432.CCR-08-2268. Clin Cancer Res. 2009. PMID: 19228741 Free article.
Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis.
Abildgaard MO, Borre M, Mortensen MM, Ulhøi BP, Tørring N, Wild P, Kristensen H, Mansilla F, Ottosen PD, Dyrskjøt L, Ørntoft TF, Sørensen KD. Abildgaard MO, et al. Among authors: sorensen kd. Int J Cancer. 2012 Feb 15;130(4):885-95. doi: 10.1002/ijc.26097. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21445975 Free article.
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD. Kristensen H, et al. Among authors: sorensen kd. Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642. Clin Cancer Res. 2014. PMID: 24737792
140 results